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OBJECTIVES: To investigate the impact of comorbid cardiovascular disease (CVD) 
on antidiabetic medication adherence. METHODS: Eligibility and claims data (2002–
2004) were used to identify patients ≥40 years of age with a diagnosis of type 2 
diabetes concurrent with hypertension (HYPT), coronary artery disease (CAD), and/
or heart failure (HF), and at least two prescription ﬁlls for an antidiabetic medication. 
Medication adherence was assessed using proportion of days covered ≥0.8. Multivari-
able logistic regressions were used to assess CVD and other risk factors associated 
with nonadherence with antidiabetic medication using 2004 data. RESULTS: A total 
of 16,922 patients were identiﬁed. Patients with two comorbid CVD were more likely 
to use or be adherent with combination cardiovascular and antidiabetic medications 
[HYPT + CAD (79%/28%, represented as proportion of use/adherent rate), HF + 
CAD (88%/31%)] than those with a single comorbid CVD [HYPT (68%/21%), CAD 
(65%/21%), and HF (72%/21%), respectively, p < 0.0001]. The adherence rate for 
use of both antidiabetic and cardiovascular medications was only 24%. The major 
signiﬁcant predictors of diabetic medication nonadherence included no ﬁll of 
(OR:2.62, 95% CI:2.28–3.01) or nonadherent with (OR:3.43, CI:3.13–3.75) cardio-
vascular medication; MediCal-only eligibility (OR:1.76, CI:1.62–1.91 vs. MediCal-
Medicare eligibility); nonompliance with diabetes care guidelines (no eye examination, 
no LDL test, and less than two HbA1c tests during 2004) (OR:1.48, CI:1.37–1.59); 
a greater number of inpatient (OR:1.17, CI:1.10–1.24) or diabetes-related inpatient 
visits (OR:1.41, CI:1.06–1.87); Black race (OR = 1.47, CI: 1.29–1.66 vs. White); type 
of comorbid CVD vs. HF + CAD [HYPT (OR:0.73, CI:0.65–0.81), CAD (OR:0.73, 
CI:0.67–0.86), HYPT + CAD (OR:0.76, CI:0.67–0.86)]; two or more cardiovascular 
medication ﬁlls (OR:1.35, CI:1.18–1.55). CONCLUSIONS: CVD comorbidity and 
nonadherence with cardiovascular medications and diabetes care guidelines were 
major signiﬁcant factors associated with nonadherence to antidiabetic medications in 
a California Medicaid sample. Patient nonadherence behaviors should be considered 
when providing care for diabetes patients with comorbid CVD.
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OBJECTIVES: As individual treatment guidelines for diabetes, dyslipidemia and 
hypertension have evolved with more aggressive treatment targets, there may be an 
unintended consequence of poor medication adherence in patients having all three 
conditions. The study objective was to investigate how patient health beliefs affect 
medication adherence in patients with coexisting diabetes, dyslipidemia and hyperten-
sion. METHODS: An online survey was administered in December 2008 to iGuard.
org members. Patients taking at least 1 medication for diabetes, dyslipidemia and 
hypertension were invited to participate in the nationwide survey (n = 2150). Survey 
items included demographics, the Medication Adherence Report Scale (MARS)—
(score = 5–25), potential adherence barriers and adherence trade-off scenarios. Patients 
were assigned a dominant health belief among the three disease states based on 
responses to the trade-off scenarios. Medication adherence rates between diabetes and 
hypertension health belief groups (dyslipidemia group excluded due to small sample 
size) and trade-off scenario selections were compared using z-tests. RESULTS: A total 
of 325 patients completed the survey, 218 patients demonstrated a dominate health 
belief for diabetes, 81 for hypertension, 13 for dyslipidemia and 13 with no dominate 
health belief. In trade-off scenarios, patients consistently stated they would choose 
taking diabetes medications over hypertension and dyslipidemia medications. (p < 
0.01) Complete adherence (MARS score = 25) with diabetes medications was higher 
in the diabetes health belief group (39.4%) compared to hypertension health belief 
group (22.2%) (p = 0.008); however there was no difference between the groups with 
complete adherence to hypertension (p = 0.811) or dyslipidemia (p = 0.278) medica-
tions. CONCLUSIONS: Diabetes therapy was considered the most important therapy 
to the majority of patients with coexisting diabetes, dyslipidemia and hypertension. 
However, in patients who considered hypertension therapy most important, there was 
signiﬁcantly less adherence to diabetes medications while exhibiting similar adherence 
to hypertension and dyslipidemia medications. These insights could be considered by 
clinicians when assessing adherence in these complex patients.
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OBJECTIVES: Despite numerous studies on medication adherence, there is little 
research on the ﬁrst prescription ﬁll rate. Our study used claims data from electronic 
prescribers to calculate ﬁrst ﬁll failure rate for antihypertensive prescriptions. 
METHODS: This retrospective study combined administrative, medical and pharmacy 
claims data from a health plan to ﬁnd the percentage of unclaimed, ﬁrst ﬁll antihy-
pertensive prescriptions, the primary outcome. Adult members with new antihyper-
tensive prescriptions prescribed by an electronically prescribing physician were eligible 
for inclusion. We allowed only prescriptions written by physicians who were electroni-
cally prescribing in order to capture antihypertensive prescriptions that would likely 
be adjudicated with a claim captured. Each antihypertensive prescription was assigned 
one outcome: paid claim (patient obtained prescription) and denied claim (unclaimed 
prescription). RESULTS: The cohort consisted of 14,693 new antihypertensive pre-
scriptions prescribed by 164 electronically prescribing physicians. First ﬁll failure rate 
was 15.6% for prescriptions which affected 24.3% of patients. We examined the 
accuracy of this new methodology by verifying the prescription rate through medical 
record abstraction. Chart review occurred for 183 of the 200 charts. There were 254 
antihypertensives prescribed, of which 247 (97.2%) had a matching pharmacy claim. 
Our methodology identiﬁed 97.2% of the prescribed antihypertensives and implies 
that 2.8% of prescriptions would not have been identiﬁed. CONCLUSIONS: Using 
electronic prescribers to proxy electronic prescribing is a new method for assessing 
ﬁrst ﬁll rates. The intent was to identify most of the prescribed antihypertensives so 
that matching pharmacy claims would determine whether the prescription was 
obtained. With a potential error rate of 2.8% of prescriptions, this methodology 
appears sensitive and accurate to determine adherence to ﬁrst ﬁll prescriptions. Future 
research should examine the correlation between the use of electronic prescriber data 
and electronic prescriptions.
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OBJECTIVES: To compare medication adherence among patients initiating single-pill 
combination (SPC) versus multi-pill combination (MPC) lipid-modifying therapies. 
METHODS: Administrative claims data from the nationally representative Health-
Core Integrated Research Database (HIRD®), representing 32.1 million fully insured 
US members, was used to identify patients who newly initiated SPC therapy (simvas-
tatin/ezetimibe SPC, simvastatin/niacin SPC, or lovastatin/niacin SPC) or equivalent 
medications dispensed as MPC therapy from January 2005 through November 2008. 
Adherence to therapy was compared between SPC and MPC groups and measured 
using the National Quality Forum-endorsed proportion of days of medication cover-
age (PDC) metric. Multivariate regression models were used to control for baseline 
differences between groups such as demographic characteristics, co-morbid condi-
tions, and health resource utilization and to estimate the association between type of 
treatment group and optimal adherence (PDC ≥ 0.80). RESULTS: A total of 42,460 
patients [38,847 SPC, age 56.3 ± 12 (mean ± SD), 55% men; 3,613 MPC, age 54.8 
± 11.6, 62% men] were identiﬁed. The mean PDC was 0.76 and 0.70 in the ﬁrst 3 
months of treatment, 0.54 and 0.45 in the second 3 months, and 0.50 and 0.41 for 
the remaining 30 months of follow-up for the SPC and MPC groups, respectively (p 
< 0.01 for each time period). This observed trend in sustained higher PDC for the SPC 
group compared to the MPC group remained even after controlling for baseline patient 
characteristics. Furthermore, multivariate logistic regression indicated that SPC 
patients were 31% more likely to be optimally adherent to treatment than MPC 
patients (OR = 1.31; 95% CI: 1.27–1.35; p < 0.01). CONCLUSIONS: Medication 
adherence was signiﬁcantly higher among patients receiving single-pill combination 
therapies compared to multi-pill combination therapies. The results suggest single-pill 
therapies may improve health outcomes in patients due to improved medication adher-
ence. Single-pill dyslipidemia therapies, where indicated, may be an important addition 
to health plan drug formularies because of their improved medication adherence 
proﬁle.
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OBJECTIVES: Although hypertension is a major risk factor for cardiovascular disease, 
medication adherence to hypertensive medications is low. Previous research identifying 
factors inﬂuencing adherence have focused primarily on broad, population-based 
approaches. Identifying speciﬁc barriers for an individual is more useful in designing 
meaningful interventions. Using customized telephonic outreach, we examined the 
speciﬁc barriers inﬂuencing hypertensive patients’ non adherence in order to identify 
targeted interventions. METHODS: Sample represented members from a health plan 
in 2008 with ≥2 prescriptions for hypertensive medications. Non adherent members 
had a Medication Possession Ratio (MPR) of <80% for at least one of their hyper-
tensive drugs. Telephone script was based on the “target” drug with the lowest MPR. 
Study was implemented in fall 2008. RESULTS: Response rate was 28.2% (n = 8692); 
22.6% commercial and 49.8% Medicare respondents. Mean age was 63.4, 54.3% 
were female; mean MPR was 61% for the target drug. Majority of respondents 
(∼60%) had adherence levels between 60–79%. However, only 58.2% of Medicare 
and 60.4% of commercial respondents reported “missing a dose of medication”. 
Primary reason was forgetfulness (61.8% Medicare; 60.8% commercial) followed by 
